Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a group therapy program help young adults navigate psychiatric challenges?

NCT ID NCT07772180

Symptom relief Sponsor: Max-Planck-Institute of Psychiatry Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study is testing a new group therapy program called CHANGE, designed for young adults aged 18-25 with psychiatric disorders. The program consists of 8 weekly sessions covering topics like transition to adulthood, suicidality, media addiction, and communication. The goal is to see if the therapy is feasible and acceptable to participants, and whether it might improve their self-efficacy, motivation, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CHANGE, a modularized cognitive behavioral group psychotherapy
What this could lead to
If successful, this therapy could offer a structured, group-based approach to help young adults with psychiatric disorders build coping skills and improve their quality of life.
What could go wrong
This is a small, early-stage feasibility study without a control group, so it can't prove the therapy works. Results may not generalize, and individual responses may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 25 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>=18 years and \< 26 years 2. Ability to provide written informed consent Exclusion Criteria: 1. Age \< 18 years, age \>= 26 years 2. Lack of ability to provide written informed consent 3. Severe concomitant neurological or internal medical diseases 4. Severe cognitive impairment (IQ \< 80, severe learning disability, brain damage or pervasive developmental disorder) 5. Lack of eligibility for psychotherapy (e.g., insufficient language proficiency, hostile or uncooperative behavior) 6. Acute risk of self-harm or harm to others, including acute psychosis, acute mania, or acute suicidal behavior 7. Acute substance-based addiction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psychiatric disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psychiatric disorder Suicidal Ideation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psychiatric disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Max-Planck-Institute of Psychiatry

    Munich, 80804, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.